MMHP
TAK icon

Murphy Middleton Hinkle & Parker’s Takeda Pharmaceutical TAK Stock Holding History

Murphy Middleton Hinkle & Parker’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-714
Closed -$467K – 211
2025
Q4 		$467K Buy
+714
New +$10.2K 0.23% 96

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Murphy Middleton Hinkle & Parker's TAK Position: Q1 2026 in Review

Murphy Middleton Hinkle & Parker sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 714 shares — an estimated $467K sold.

Murphy Middleton Hinkle & Parker first reported a position in TAK in Q4 2025 and held it in 1 quarter. The position peaked at $467K in Q4 2025. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Murphy Middleton Hinkle & Parker reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Murphy Middleton Hinkle & Parker sold 714 Takeda Pharmaceutical shares in Q1 2026, an estimated $467K.
  • Murphy Middleton Hinkle & Parker first reported a position in Takeda Pharmaceutical in Q4 2025 and held it in 1 quarter.
  • Murphy Middleton Hinkle & Parker's Takeda Pharmaceutical position peaked at $467K in Q4 2025.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Murphy Middleton Hinkle & Parker's 13F filing for Q1 2026, filed 15 Apr 2026.